Abstract: Background and objective: Rivaroxaban is a new oral anticoagulant for stroke prevention in patients with non-valvular atrial fibrillation (NVAF), which has less drug–food interaction than warfarin. We conducted this prospective randomized study to evaluate the metabolic benefits as well as the safety and efficacy with rivaroxaban versus warfarin in patients with NVAF following radiofrequency catheter ablation (RFCA). Methods: From April to July 2014, 60 patients with NVAF undergoing RFCA were prospectively enrolled in our study. Following RFCA, all patients were randomly assigned to receive rivaroxaban (Group R, n=30) or warfarin (Group W, n=30). Metabolic indices including serum total protein, albumin, globulin, and high-density lipoprotein (HDL) as well as bleeding, stroke, and systemic thromboembolism events were evaluated and compared during follow-up after 15, 30, 60, and 90 d of RFCA procedure. Results: Serum total protein, albumin, globulin, and HDL levels were all significantly elevated at each follow-up stage in Group R when compared to the baseline (P<0.05 respectively). In Group W, the metabolic indices decreased at first and then had an increasing trend. There were no deaths or thromboembolic complications in each group. The prevalence of total bleeding complications was similar between Group R and Group W (11/30, 36.7% vs. 10/30, 33.3%, P=0.79). Conclusions: Patients with NVAF receiving rivaroxaban after RFCA procedures appear to benefit from a metabolic perspective compared with warfarin, providing practical clinical reference for the choice of the anticoagulant. Rivaroxaban seems to be as safe and effective in preventing thromboembolic events as warfarin for these patients.

利伐沙班在非瓣膜病性房颤患者经导管射频消融术后抗凝中的代谢获益

[1]Ansell, J., Hirsh, J., Hylek, E., et al., 2008. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest, 133(6 Suppl.):160S-198S.

[2]Camm, A.J., Amarenco, P., Haas, S., et al., 2016. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur. Heart J., 37(14):1145-1153.

[3]Cappato, R., Calkins, H., Chen, S.A., et al., 2010. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ. Arrhythm. Electrophysiol., 3(1):32-38.

[4]Caso, G., Feiner, J., Mileva, I., et al., 2007. Response of albumin synthesis to oral nutrients in young and elderly subjects. Am. J. Clin. Nutr., 85(2):446-451.

[5]Cheng, H., Dai, Y.Y., Jiang, R.H., et al., 2014. Non-pulmonary vein foci induced before and after pulmonary vein isolation in patients undergoing ablation therapy for paroxysmal atrial fibrillation: incidence and clinical outcome. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 15(10):915-922.

[6]Dillier, R., Ammar, S., Hessling, G., et al., 2014. Safety of continuous periprocedural rivaroxaban for patients undergoing left atrial catheter ablation procedures. Circ. Arrhythm. Electrophysiol., 7(4):576-582.

[7]Doweiko, J.P., Nompleggi, D.J., 1991. Role of albumin in human physiology and pathophysiology. J. Parenter. Enteral Nutr., 15(2):207-211.

[8]Duly, E.B., Grimason, S., Grimason, P., et al., 2003. Measurement of serum albumin by capillary zone electrophoresis, bromocresol green, bromocresol purple, and immunoassay methods. J. Clin. Pathol., 56(10):780-781.

[9]Eitel, C., Koch, J., Sommer, P., et al., 2013. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation. Europace, 15(11):1587-1593.

[10]Fox, K.A., Piccini, J.P., Wojdyla, D., et al., 2011. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur. Heart J., 32(19):2387-2394.

[11]Francart, S.J., Hawes, E.M., Deal, A.M., et al., 2014. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb. Haemost., 111(6):1133-1140.

[12]Gaita, F., Caponi, D., Pianelli, M., et al., 2010. Radiofrequency catheter ablation of atrial fibrillation: a cause of silent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation. Circulation, 122(17):1667-1673.

[13]Heidbuchel, H., Verhamme, P., Alings, M., et al., 2013. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace, 15(5):625-651.

[14]Hussein, A.A., Martin, D.O., Saliba, W., et al., 2009. Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy. Heart Rhythm, 6(10):1425-1429.

[15]Jackson, A.A., Phillips, G., McClelland, I., et al., 2001. Synthesis of hepatic secretory proteins in normal adults consuming a diet marginally adequate in protein. Am. J. Physiol. Gastrointest. Liver Physiol., 281(5):G1179-G1187.

[16]January, C.T., Wann, L.S., Alpert, J.S., et al., 2014. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation, 130(23):2071-2104.

[17]Jiang, R.H., Po, S.S., Tung, R., et al., 2014. Incidence of pulmonary vein conduction recovery in patients without clinical recurrence after ablation of paroxysmal atrial fibrillation: mechanistic implications. Heart Rhythm, 11(6):969-976.

[18]Kim, J.S., Jongnarangsin, K., Latchamsetty, R., et al., 2013. The optimal range of international normalized ratio for radiofrequency catheter ablation of atrial fibrillation during therapeutic anticoagulation with warfarin. Circ. Arrhythm. Electrophysiol., 6(2):302-309.

[19]Kwak, J.J., Pak, H.N., Jang, J.K., et al., 2010. Safety and convenience of continuous warfarin strategy during the periprocedural period in patients who underwent catheter ablation of atrial fibrillation. J. Cardiovasc. Electrophysiol., 21(6):620-625.

[20]Lakkireddy, D., Reddy, Y.M., di Biase, L., et al., 2014. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J. Am. Coll. Cardiol., 63(10):982-988.

[21]Patel, M.R., Mahaffey, K.W., Garg, J., et al., 2011. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med., 365(10):883-891.

[22]Piccini, J.P., Stevens, S.R., Lokhnygina, Y., et al., 2013. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J. Am. Coll. Cardiol., 61(19):1998-2006.

[23]Santangeli, P., di Biase, L., Horton, R., et al., 2012. Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: evidence from a meta-analysis. Circ. Arrhythm. Electrophysiol., 5(2):302-311.

[24]Takahashi, A., Kuwahara, T., Takahashi, Y., 2009. Complications in the catheter ablation of atrial fibrillation: incidence and management. Circ. J., 73(2):221-226.

[25]Thalacker-Mercer, A.E., Johnson, C.A., Yarasheski, K.E., et al., 2007. Nutrient ingestion, protein intake, and sex, but not age, affect the albumin synthesis rate in humans. J. Nutr., 137(7):1734-1740.

[26]Vazquez, S.R., Johnson, S.A., Rondina, M.T., 2010. Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation. Thromb. Res., 126(2):e69-e77.